The gene encoding the herpes simplex virus type I (HSV-1) glycoprotein C (gC) was isolated and cloned into a vaccinia virus insertion vector, and the resulting vaccinia-gC vector was used to construct a recombinant vaccinia virus that expressed gC (VVgC5). Infection of cells with VVgC5 resulted in cell surface expression of authentic HSV-1 gC. HSV-1 gC-specific neutralizing antibodies were produced in VVgC5-immunized mice, and lymphocytes exhibited an HSV-l-specific proliferation response in vitro following infection. More importantly, VVgC5-immunized mice were resistant to subsequent lethal HSV-1 challenge.
INTRODUCTION
Herpes simplex virus type l (HSV-I) encodes at least seven glycoproteins. These membrane glycoproteins, which are exposed on the surface of infected cells as well as on intact virions, are involved in virus entry into susceptible cells and probably influence tissue specificity and virus host range (for review, see Spear, 1985) . It is important to elucidate the contribution of individual glycoproteins in eliciting host immune responses to HSV-1 infection, since such knowledge is essential for the design of vaccines. Glycoprotein C (gC) is of particular interest because it acts as a receptor for the C3b component of complement and is one of the most abundant viral surface antigens (Glorioso et al., 1984) . Immunoprecipitating antibody specific for gC, along with that for gB, predominates in the sera of mice infected with HSV-1 (Glorioso et al., 1984) , and immunization of mice with purified gC induces a neutralizing antibody response that protects against lethal HSV-1 challenge (Schrier et al., 1983; Roberts et al., 1985) . Glycoprotein C has also been reported as an important antigen for HSV-l-specific memory cytotoxic T lymphocytes (CTL) (Glorioso et al., 1985) .
Mice immunized with recombinant vaccinia viruses expressing either HSV-1 gD (Cremer et al., 1985; Paoletti et al., 1984) or gB (Cantin et al., 1987) were shown to survive lethal HSV-1 infection. In addition, recombinant vaccinia viruses expressing gG (Sullivan & Smith, 1987) and gI (Sullivan & Smith, 1988) have been constructed to identify and characterize the protein products of these genes. To evaluate the role of gC in evoking a protective immune response, we have constructed a recombinant vaccinia virus, VVgC5, that contains the HSV-1 gC gene. In this report, we show that VVgC5 expresses authentic HSV-1 gC, and demonstrate that immunization with VVgC5 induces an immune response in mice that is sufficient for protection from lethal infection with HSV-1.
Antibodies. D4.2 and D4.8, mouse monoclonal IgG2a anti-HSV-1 gD and gB antibodies respectively, were obtained from Dr M. Trousdale (City of Hope National Medical Center, Duarte, Ca., U.S.A.), raised in BALB/c mice as ascites and affinity-purified on Protein A Sepharose. Tissue culture fluid containing Fd8 (Koga et al., 1986) , a mouse monoclonal IgG2a anti-HSV-1 gC antibody, was a gift from Dr R. Whitley (University of Alabama at Birmingham, Birmingham, Ala, U.S.A.). It was concentrated by vacuum dialysis and quantified by a v2a heavy chain-specific ELISA (Hiernaux et al., 1989) . Mouse monoclonal 19S ascites (Showalter et al., 1981) , an IgG2a anti-HSV-1 gC antibody, was a gift from Dr M. Zweig (National Cancer Institute, Frederick, Md., U.S.A.).
Construction ofplasmids. Plasmid pTI (obtained from Dr E. Wagner, University of California, Irvine, Ca., U.S.A.) contains a 3.3 kb DNA fragment of HSV-1 (strain KOS) from a SalI site (map unit 0.621) approximately 1500 bp upstream from the start of gC translation to a BamHI site (0.643) 380 bp downstream from the end of gC translation (Frink et al., 1983) (Fig. 1) . The phage vector M13mpl8 was used for oligonucleotide-directed mutagenesis of single-stranded phage DNA (Kunkel et aL, 1987) . Routine DNA manipulations were similar to those described by Maniatis et al. (1982) . Oligonucleotides were made with an Applied Biosystems 381 DNA synthesizer, and the construction of plasmids was verified by sequencing as described by Zagursky et al. (1985) .
Immunoprecipitation. Approximately 3 x 106 Vero cells were washed with methionine-free medium (Sigma), incubated for 1 h and infected at an m.o.i, of 30. After 1 h, the virus inoculum was removed and the cells were labelled for 12 h with [35S]methionine (100 ~tCi) in MEM containing one-tenth the normal concentration of methionine and 1% foetal bovine serum. Cell extracts were prepared as described previously (Eberle & Courtney, 1978) , with a final volume of 300 p.1.
For immunoprecipitation, 30 lal of extract was combined with 3 ~tl of appropriate ascites fluid in a total volume of 300 ~tl containing 0.1 M-Tris-HC1 pH 7.5, 0-1 M-NaC1, 0.5 ~ NP40 and 0.1 ~ aprotinin, and rocked overnight at 4 °C. To precipitate antibody-antigen complexes, 50 p.1 of a Protein A-Sepharose solution (l : 1 suspension in incubation buffer) was added and incubated for 2 h. The pellet was washed three times with wash buffer (20 miTris-HC1 pH 7.5, 100 mM-NaC1, 1 mM-EDTA and 1 ~ NP40) and the precipitated antigens were eluted by heating to 100 °C in loading buffer before electrophoresis in a 7.5~ SDS-polyacrylamide gel (Laemmli, 1970) .
Immunofluorescence. Expression of cell surface proteins was assessed by immunofluorescence. Confluent monolayers of Vero cells were infected with the indicated crude virus stock at an m .o.i. of 5. At 15 h post-infection, cells were harvested by brief treatment with trypsin and washed immediately by centrifugation. Cells were treated and washed throughout with phosphate-buffered saline (PBS) containing 2% calf serum and 0.2~ sodium azide. Viable cells (106) were stained with 10 lal diluted antiserum as described (Elkins et aL, 1987) , using fluoresceinconjugated goat anti-mouse IgG (lot number 1591-7; Southern Biotecbnology). Washed cells were fixed in 0-5~ paraformaldehyde and examined for green fluorescence and forward light scatter on a FACStar Plus flow cytometer (University of Tennessee Memorial Research Hospital, Knoxville; 488 nm argon laser at 200 mW). Histograms were constructed and analysed with Becton-Dickinson software over a five decade logarithmic scale, but only the top four decades are shown. Saturating concentrations of primary and secondary antibodies were determined in preliminary experiments by titration on HSV-l-infected Vero cells; 50 ~tg/ml Fd8 (anti-gC), 50 ~tg/ml D4.2 (anti-gD) and 50 ~tg/ml fluorescein-conjugated goat anti-mouse IgG were used throughout.
Immunization of animals and HSV-1 challenge. Seven week old BALB/cAnNHsdBR mice (Harlan Sprague Dawley) were injected intraperitoneally with 103 to 108 p.f.u, of HSV-1 (McKrae) and observed for 14 days to establish a lethal challenge dose of HSV-1. A dose of 5 x 106 p.f.u, of HSV-1 was used for subsequent challenge. Five week old BALB/c mice were immunized by intradermal injection into the footpad with either PBS, HSV-1 (KOS), VVgC5 or a control vaccinia virus that does not contain the gC gene. Sera were collected 2 weeks later and the animals challenged as described above. Mice were observed for 14 days. HSV-1 neutralizing antibody titres were determined by complement-dependent neutralization as described previously (Martin & Rouse, 1987) . Female C3H/HenHsdBR mice were purchased from Harlan Sprague Dawley and used as young adults.
Immunoblot assay. Glycoprotein C-specific antibodies were detected in serum samples using an indirect immunodot blot assay. Purified gC was prepared by immunoaffinity chromatography as described previously (Turtinen et al., 1986) and spotted (0.5 ~tg/well) onto nitrocellulose using a microfiltration apparatus. All incubation periods were performed at room temperature for 1 h. After an initial incubation, the wells were washed with TBST (10 mM-Tris-HCl pH 7-0, 150 mM-NaC1, 0.05 ~ Tween), blocked by incubation with TBST containing 1 ~ bovine serum albumin (BSA) and washed. Appropriately diluted serum samples were added to the individual wells; the plates were incubated and washed. The nitrocellulose sheet was removed, free protein binding sites were blocked again by incubation with TBST/BSA, and an optimum dilution of affinity-purified goat anti-mouse IgG alkaline phosphatase conjugate (Bio-Rad) was added. Specifically bound antibody was subsequently detected by colour development after the addition of 5-bromo-4-chloro-3-indolylphosphate (BCIP, 4.5 x 10-* M; Bio-Rad), andp-nitro blue tetrazolium chloride (NBT, 3.8 x 10-* M; Bio-Rad) in 100 mM-Tris-HC1 pH 9.5, 100 mM-NaC1, 5 mM-MgC1. Colour development was stopped by washing the nitrocellulose sheet in distilled water. The antibody titre was defined as the highest dilution that gave a visibly coloured well.
Lymphoproliferation. Spleen cells were obtained from C3H/HeNHsdBR mice (Harlan Sprague Dawley) 4 weeks after immunization. Antigen-specific proliferative response to u.v.-inactivated HSV-I was measured in vitro as described previously . Briefly, spleen cells were pooled from groups of four mice and cultured with u.v.-inactivated HSV-1 in replicates of 12 wells for 5 days. On the last day of culture, 0.5 ~tCi of [3H]thymidine was added to each well and incorporation of [3H]thymidine into cellular DNA was measured 16 h later.
RESULTS AND DISCUSSION
A detailed analysis of the portion of the HSV-1 genome that contains the gC gene was reported previously, including the sequence of the entire coding region (Frink et al., 1983) . To isolate only the gC structural gene, a 3.3 kb SalI-BamHI DNA fragment containing both regulatory and structural gC sequences was cloned into the phage vector M13mpl8. Using oligonucleotide-directed mutagenesis of single-stranded phage DNA (Kunkel et al., 1987) , a new BamHI site was generated 9 bp upstream from the ATG used for translation initiation of the gC gene. The resultant 2.0 kb BamHI fragment, which contained the entire gC coding region, was isolated and cloned in the correct orientation into a unique BamHI site of the vaccinia virus plasmid vector pVV1 and designated pgC5 (Fig. 1) . Thus, the distance from the start of gC translation to the vaccinia virus growth factor (VGF) promoter that directs gC transcription was minimized. The vector pVV 1 uses the VGF promoter, an early viral promoter, to express foreign genes, and contains several unique restriction sites downstream from the VGF promoter (J. E. Weir et al., unpublished) . This insertion vector should be useful for construction of other vaccinia virus recombinants when it is desirable to have the gene product in question expressed early during vaccinia virus infection. One recent report suggests the need for early expression in vaccinia virus recombinants for optimal immune responses to certain foreign proteins (Coupar et at., 1986) . Recombinant vaccinia virus was made using pgC5 as described earlier (Mackett et al., 1984) , purified and designated VVgC5.
To establish that VVgC5 expressed an authentic gC, we used a monoclonal antibody that is specific for HSV-1 gC (19S; Showalter et al., 1981) to immunoprecipitate proteins from infected cell extracts. Vero cells were infected with either HSV-1, VVgC5 or a control vaccinia virus that does not contain the gC gene, and labelled with [3SS]methionine for 12 h. Extracts were immunoprecipitated with either anti-gC antibody or non-specific antibody and analysed by SDS-PAGE (Laemmli, 1970) (Fig. 2) . A precipitated protein of approximately 130 000 Mr was detected using anti-gC antibody in both HSV-and VVgC5-infected cell extracts (lanes 2 and 4, Fig. 1 . Construction of a recombinant vaccinia virus containing the HSV-1 gC gene. The approximate location of the gC gene on the HSV-1 genome is shown, with the restriction sites used to construct the plasmid pTI. The coding sequences of gC are indicated by the stippled box. The SalIBamHI fragment was cloned into the phage M13mpl8 and a new BamHI site was generated by oligonucleotide mutagenesis to give mpl8-gC2. The 2.0 kb BamHl gC fragment from mgl8-gC2 was cloned into a vaccinia virus insertion vector to give the plasmid pgCS. The thymidine kinase (TK) gene and VGF promoter are indicated. Recombinant vaccinia virus VVgC5 was made from pgC5 as described in Methods. ). Histograms were generated by flow cytometry as described in Methods.
with anti-gC or anti-gD antibodies and fluorescein-conjugated goat anti-mouse IgG were then analysed by flow cytometry as described previously (Elkins et al., 1987) . Fd8 (anti-gC) and D4.2 (anti-gD) antibodies were both of the same isotype (IgG2a), were used at the same concentration, and thus served as reciprocal controls for non-specific binding. The resulting histograms, which plot relative cell number against log10 fluorescence intensity, are shown in Fig. 3 ; only the results for the secondary antibody alone (background) and anti-gC plus secondary antibody are shown. Profiles for cells alone without any secondary antibody (autofluorescence control) essentially overlapped those for secondary antibody alone (data not shown); both were therefore considered negative. To estabish relative numbers of positive cells, the profiles of the secondary antibody alone groups were computer-subtracted from the test sample profiles.
Neither mock-infected cells (Fig. 3a) nor vaccinia virus-infected cells (Fig. 3d ) expressed detectable cell surface gC or gD (data not shown). HSV-1-infected cells (Fig. 3 b) expressed both gC (90 ~ positive) and gD (93 % positive; histogram not shown), and served as positive controls for infection as well as the ability to detect both proteins. VVgC5-infected ceils (Fig. 3c ) expressed cell surface gC (93% positive), but no detectable gD (histogram not shown), confirming that the apparent detection of gC was not due to non-specific binding. Different anti-gC monoclonal antibodies were used for precipitation and immunofluorescence because of their availability. This may account for the different levels of gC observed by immunoprecipitation and immunofluorescence in HSV-1 compared to VVgC5-infected cells. However, each antibody, previously characterized for specificity, was able to recognize the protein synthesized by VVgC5. Thus, in vitro infection of Vero cells with the VVgC5 recombinant virus results in production of gC protein and insertion of the protein into the cell membrane in a manner similar to that in an HSV-l-infected cell. Mice were bled on the day of challenge and the available serum from individual mice was used to determine the neutralization titre as described (Martin & Rouse, 1987) . Values are expressed as the mean titre + standard error. The number of sera tested per group was seven, seven, eight and nine for groups 1 to 4, respectively. t Serum samples were obtained 4 weeks later, and virus neutralization titres determined as described (Martin & Rouse, 1987) .
:~ HSV-1 gC-specific antibody titre was determined as described in Methods. Results are shown for individual mice except for the PBS-immunized group, which represents a pool of sera from 18 mice.
§ Lowest dilution tested.
To determine whether gC is produced following infection of animals in vivo with VVgC5, sera from infected mice were first tested for the presence of antibody to HSV-1. BALB/c mice were immunized intradermally with either HSV-1, VVgC5, vaccinia virus or PBS. Sera were collected 2 weeks after inoculation and assayed by complement-dependent serum neutralization. Table 1 shows that neutralizing antibody was produced in the animals that had been inoculated with VVgC5 or HSV-1, but not with vaccinia virus or PBS. That the level of neutralizing antibodies induced by HSV-1 was higher than that induced by VVgC5 is not surprising, since the immune response to HSV-1 involves a variety of viral antigens in addition to gC. When mice were challenged by intraperitoneal injection of a high dose of HSV-1, 80 to 90 ~o of the PBS-immunized mice and 60 to 80 ~ of the vaccinia virus-immunized mice succumbed to the challenge (Table 1) . In contrast, none of the HSV-l-immunized mice and only 10~ of the VVgC5-immunized mice died following challenge.
In separate experiments, we determined that mice immunized with VVgC5 produced gCspecific antibodies. The sera from female C3H/HeNHsd mice, infected with either HSV-1, VVgC5 or vaccinia virus, were collected 4 weeks after inoculation and assayed by an HSV-1 gCspecific immunodot blot (Methods) as well as by complement-dependent serum neutralization. Table 2 shows that HSV-1 neutralizing antibody was detected in mice infected with either HSV-1 or VVgC5, but not in those with vaccinia virus or PBS. Furthermore, serum from each mouse in the HSV-1 and VVgC5 groups contained antibody specific for HSV-1 gC.
To determine whether VVgC5 is capable of eliciting a cell-mediated immune response to gC, spleen cells from immunized mice were examined for their ability to proliferate in vitro upon stimulation with inactivated HSV-1. In this experiment (Table 3) , HSV-l-specific lymphoproliferation was observed using cells from VVgC5-and HSV-l-immunized mice, but not in cells from PBS-or vaccinia virus-immunized mice. Thus, VVgC5 is capable of activating cells in vivo that can be restimulated to proliferate in vitro by HSV-1.
The vaccinia-gC recombinant virus, VVgC5, described in this report should help further to elucidate the role of gC, particularly since vaccinia virus expression vectors are capable of stimulating humoral and cell-mediated immunity (Moss & Flexner, 1987) . We have demonstrated that VVgC5 synthesizes authentic HSV-1 gC that is expressed at the cell surface at levels suffÉcient to induce neutralizing gC-specific antibodies effectively, prime cells for an in vitro lymphoproliferative respone and immunize mice against HSV-1 challenge. It has previously been shown that purified gC can induce immunity in mice sufficient to protect against lethal doses of challenge virus (Schrier et al., 1983; Roberts et al., 1985) . However, the availability of a vaccinia virus recombinant that expresses gC will facilitate studies that address the role of gC in aspects of both humoral and cell-mediated immunity that are difficult to approach with purified gC. Evaluation of the full spectrum of immune responses induced by VVgC5, and comparison to the responses induced by the other vaccinia virus recombinants, should lead to a better understanding of the relative contribution of each glycoprotein to HSV-1-specific immunity. 
